Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer | Zendy

Matthew D. Hellmann | Zendy; Luis PazAres | Zendy; Reyes Bernabé | Zendy; Bogdan Żurawski | Zendy; SangWe Kim | Zendy; Enric Carcereny | Zendy; Keunchil Park | Zendy; Aurelia Alexandru | Zendy; Lorena Lupinacci | Zendy; Emmanuel de la Mora Jimenez | Zendy; Hiroshi Sakai | Zendy; István Albert | Zendy; A. Vergnenègre | Zendy; Solange Peters | Zendy; Konstantinos Syrigos | Zendy; Fabrice Barlési | Zendy; Martin Reck | Zendy; Hossein Borghaei | Zendy; Julie R. Brahmer | Zendy; Kenneth J. O’Byrne | Zendy; William J. Geese | Zendy; Prabhu Bhagavatheeswaran | Zendy; Sridhar K. Rabindran | Zendy; Ravi S. Kasinathan | Zendy; Faith E. Nathan | Zendy; Suresh S. Ramalingam | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Author(s) -

Matthew D. Hellmann,

Luis PazAres,

Reyes Bernabé,

Bogdan Żurawski,

SangWe Kim,

Enric Carcereny,

Keunchil Park,

Aurelia Alexandru,

Lorena Lupinacci,

Emmanuel de la Mora Jimenez,

Hiroshi Sakai,

István Albert,

A. Vergnenègre,

Solange Peters,

Konstantinos Syrigos,

Fabrice Barlési,

Martin Reck,

Hossein Borghaei,

Julie R. Brahmer,

Kenneth J. O’Byrne,

William J. Geese,

Prabhu Bhagavatheeswaran,

Sridhar K. Rabindran,

Ravi S. Kasinathan,

Faith E. Nathan,

Suresh S. Ramalingam

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - Uncategorized

Resource type - Journals

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1910231

Subject(s) - nivolumab , ipilimumab , medicine , lung cancer , oncology , cancer , immunotherapy

In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research